Alzheimer's disease is with 60 to 70 % the most common cause of dementia in old age. In contrast to the age-dependent, sporadic form of Alzheimer's, the familial, genetically caused form can also occur in young adults from 30 years of age.

Definitive diagnosis of Alzheimer's disease can only be established post mortem by brain autopsy to detect the neuropathological changes (plaques and neurofibrillary tangles). In vivo diagnosis (probable Alzheimer's disease) is based primarily on clinical identification of dementia syndrome and exclusion of possible reversible causes.

Clinical diagnosis is unreliable, particularly in the early disease stages, and requires additional measurable biomarkers with high diagnostic reliability. The concentrations of soluble beta-amyloid 1-42 (Aβ1-42) and tau proteins (total tau (T-tau) and phosphorylated tau (P-tau) in the CSF reflect the Alzheimer's specific neuropathological changes in the brain, allowing discrimination from healthy persons.  The ratio of beta-Aβ1-42 to Aβ1-40 in CSF can contribute to differentiating Alzheimer's disease from vascular dementia.

Imaging techniques can also be used to support early and differential diagnostics.

ProductProbenmaterialRegulatory statusOrder no.
Beta-Amyloid (1-42) ELISACSFCEEQ 6521-9601-L
Beta-Amyloid (1-40) ELISACSFCEEQ 6511-9601-L
Beta-Amyloid (1-42) high sensitive ELISA PlasmaRUO*EQ 6521-9601
Beta-Amyloid (1-40) high sensitive ELISAPlasmaRUO*EQ 6511-9601

*For research use only in the sense of EU directive 89/79/EC